1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 40 to 90
Sponsor: Pharmaceutical / Industry
Protocol IDs: AVO108943, NCT00470834
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS31, EudraCT number: 2008-008604-40, NCT00884273
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Adult
Sponsor: NCI
Protocol IDs: SWOG-9346, SWOG-9346, CAN-NCIC-PR8, CALGB-9594, ECOG-S9346, EORTC-30985, CAN-NCIC-JPR8, INT-0162, NCT00002651, PR8
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 80
Sponsor: Other
Protocol IDs: FRE-FNCLCC-GETUG-12/0203, EU-20238, NCT00055731
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 to 79
Sponsor: Other
Protocol IDs: JCOG0401, C000000026, NCT00138008
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: No age specified
Sponsor: Other
Protocol IDs: 05-8-4, NCT00243646
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0521, NCT00288080
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2003-0819, NCT00388804
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: MRC-RADICALS-PR10, MRC-RADICALS-PR10, ISRCTN40814031, EUDRACT-2006-000205-34, EU-20767, PR13, NCT00541047
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0534, RTOG 0534, NCT00567580
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: NCI
Protocol IDs: CAN-NCIC-PR12, PR12, NCT00651326
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS28, 2008-004338-26 (EudraCT No), NCT00831233
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS30, 2008-005232-33 (EudraCT No), NCT00833248
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 4P-06-3, NCT00669162
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: NYU 08-479, NCT00878436
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: MUSC-031218, 100822, MUSC-HR-11357, NCT00103376
|
|
17.
|
Phase: Phase II
Type: Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UHN REB 00-0430-C, National Cancer Inst of Canada, NCT00188708
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 05-8538-V 01, FHCRC-05026, NCT00298155
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: OZM-001, NCT00430235
|
|
20.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-07022, 07-022, NCT00468715
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 45 to 80
Sponsor: NCI
Protocol IDs: FHCRC-6408, 6408, UWCC-UW 6408, UWCC- 06-4211-H/B, NCT00516815
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0621, RTOG 0621, NCT00528866
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CHNMC-05190, 05190, NCT00544830
|
|
24.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-06160, 06-160, MSKCC IRB 06-160, 7864, NCT00589472
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 07-316, NCT00630344
|
